Recent Research Analysts’ Ratings Changes for Phreesia (PHR)

A number of research firms have changed their ratings and price targets for Phreesia (NYSE: PHR):

• 1/9/2026 – Phreesia had its price target lowered by analysts at Citigroup Inc. from $29.00 to $25.00. They now have a “buy” rating on the stock.
• 1/9/2026 – Phreesia is now covered by analysts at Royal Bank Of Canada. They set a “moderate buy” rating and a $26.00 price target on the stock.
• 1/8/2026 – Phreesia is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $30.00 price target on the stock.
• 1/8/2026 – Phreesia was given a new $24.00 price target on by analysts at Truist Financial Corporation.
• 1/8/2026 – Phreesia is now covered by analysts at Wells Fargo & Company. They set an “overweight” rating and a $30.00 price target on the stock.
• 1/6/2026 – Phreesia was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 12/16/2025 – Phreesia had its price target lowered by analysts at Barclays PLC from $26.00 to $24.00. They now have an “overweight” rating on the stock.
• 12/10/2025 – Phreesia was given a new $29.00 price target on by analysts at Truist Financial Corporation.
• 12/10/2025 – Phreesia had its price target lowered by analysts at Mizuho from $36.00 to $28.00. They now have an “outperform” rating on the stock.
• 12/10/2025 – Phreesia had its price target lowered by analysts at Robert W. Baird from $31.00 to $25.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at Canaccord Genuity Group Inc. from $38.00 to $33.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at Citigroup Inc. from $34.00 to $29.00. They now have a “buy” rating on the stock.
• 12/9/2025 – Phreesia had its price target lowered by analysts at JPMorgan Chase & Co. from $32.00 to $29.00. They now have an “overweight” rating on the stock.
• 12/8/2025 – Phreesia is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $26.00 price target on the stock.
• 12/8/2025 – Phreesia was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 12/8/2025 – Phreesia is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $26.00 price target on the stock.
• 12/8/2025 – Phreesia had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
• 12/2/2025 – Phreesia had its price target raised by analysts at DA Davidson from $33.00 to $35.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, insider Evan Roberts sold 6,317 shares of the business’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $17.01, for a total value of $107,452.17. Following the transaction, the insider owned 834,632 shares of the company’s stock, valued at approximately $14,197,090.32. The trade was a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Amy Beth Vanduyn sold 2,602 shares of the company’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $44,260.02. Following the transaction, the senior vice president owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. This represents a 1.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,766 shares of company stock worth $1,013,817 in the last quarter. 5.50% of the stock is owned by insiders.

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.